A study suggests low platelet or low hemoglobin levels may be factors linked to COVID-19 mortality in patients with hematologic malignancies.
Patients may not have much information on chronic myeloid leukemia, and some may have a number of misunderstandings surrounding the condition. As a health care professional, what are some of these myths you can correct to better educate patients?
The underlying mechanisms of late recurrence must be investigated further, according to researchers.
Overall survival data were available for about half of the drugs.
Updated data demonstrated asciminib significantly improved the rate of MMR at 48 weeks compared with bosutinib.
Seroconversion was observed in 99% of patients with chronic myeloid leukemia.
A retrospective analysis of data identified predictors of cardiac adverse events in patients with CML undergoing treatment with tyrosine kinase inhibitors.
Patients’ age, sex, and treatment-related symptoms, as well as mothers’ education level, were significantly associated with HRQOL.
Researchers sought to determine whether there was a difference in generic or branded imatinib in treating patients with CML.
Asciminib inhibits the ABL1 kinase activity of the BCRABL1 fusion protein, by binding to the ABL myristoyl pocket.
Researchers sought to determine the accuracy of established tools in predicting the risk of cardiovascular events in patients with CML receiving TKIs.
Respondents said some essential cancer drugs had substantial out-of-pocket costs, and some posed a high risk of catastrophic expenditure.
Experts outline risk factors for PTSD and explain how PTSD can affect cancer outcomes.
A retrospective study of Medicare data showed a potential factor in nonadherence to oral cancer treatment regimens.
Cyberattacks on health care organizations may not be fully preventable, but there are ways to limit their impact on cancer care.
Researchers evaluated the benefit-risk ratio across 3 ponatinib starting doses in patients with chronic phase chronic myeloid leukemia.
Dasatinib produced responses regardless of comorbidity burden.
Researchers sought to determine the risk of hepatotoxicity for patients with CML treated with 4 newer TKIs compared with imitanib.
The AACR COVID-19 and Cancer Task Force recommends keeping changes to clinical trial practices that were prompted by the pandemic.
An analysis of a registry of patients with CML and Philadelphia chromosome-positive ALL demonstrated that ponatinib is efficacious in those with relapsed or refractory disease.